Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

PSMA-D GUL

Generic Name: PSMA-D GUL

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy

Phase 1

Active, not recruiting

Posted: 2022/09/21

Sponsor:Cellbion Co., Ltd.

ID:NCT05547061

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

MSD and CellBion Partner to Test Novel Radioligand-Immunotherapy Combination for Advanced Prostate Cancer

4 months ago

CellBion and MSD have established a groundbreaking partnership to evaluate the combination of Lu-177-DGUL radioligand therapy with Keytruda in advanced prostate cancer patients, marking Korea's first radioligand-immunotherapy trial.

CellBion's Lu-177-DGUL Shows Promise in Metastatic Prostate Cancer Treatment

8 months ago

CellBion is advancing Lu-177-DGUL, a radiopharmaceutical, for metastatic castration-resistant prostate cancer (mCRPC), aiming for conditional approval in Korea by late 2025.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy